Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238774035> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4238774035 endingPage "2204" @default.
- W4238774035 startingPage "2196" @default.
- W4238774035 abstract "Objective To evaluate the efficacy and safety of interleukin-1 receptor antagonist (IL-1Ra) in patients with rheumatoid arthritis (RA). Methods Patients with active and severe RA (disease duration <8 years) were recruited into a 24-week, double-blind, randomized, placebo-controlled, multicenter study. Doses of nonsteroidal antiinflammatory drugs and/or oral corticosteroids (≤10 mg prednisolone daily) remained constant throughout the study. Any disease-modifying antirheumatic drugs that were being administered were discontinued at least 6 weeks prior to enrollment. Patients were randomized to 1 of 4 treatment groups: placebo or a single, self-administered subcutaneous injection of IL-1Ra at a daily dose of 30 mg, 75 mg, or 150 mg. Results A total of 472 patients were recruited. At enrollment, the mean age, sex ratio, disease duration, and percentage of patients with rheumatoid factor and erosions were similar in the 4 treatment groups. The clinical parameters of disease activity were similar in each treatment group and were consistent with active and severe RA. At 24 weeks, of the patients who received 150 mg/day IL-1Ra, 43% met the American College of Rheumatology criteria for response (the primary efficacy measure), 44% met the Paulus criteria, and statistically significant improvements were seen in the number of swollen joints, number of tender joints, investigator's assessment of disease activity, patient's assessment of disease activity, pain score on a visual analog scale, duration of morning stiffness, Health Assessment Questionnaire score, C-reactive protein level, and erythrocyte sedimentation rate. In addition, the rate of radiologic progression in the patients receiving IL-1Ra was significantly less than in the placebo group at 24 weeks, as evidenced by the Larsen score and the erosive joint count. IL-1Ra was well tolerated and no serious adverse events were observed. An injection-site reaction was the most frequently observed adverse event, and this resulted in a 5% rate of withdrawal from the study among those receiving IL-1Ra at 150 mg/day. Conclusion This study confirmed both the efficacy and the safety of IL-1Ra in a large cohort of patients with active and severe RA. IL-1Ra is the first biologic agent to demonstrate a beneficial effect on the rate of joint erosion." @default.
- W4238774035 created "2022-05-12" @default.
- W4238774035 creator A5001588361 @default.
- W4238774035 creator A5004363203 @default.
- W4238774035 creator A5022630337 @default.
- W4238774035 creator A5026797171 @default.
- W4238774035 creator A5028429978 @default.
- W4238774035 creator A5037573724 @default.
- W4238774035 creator A5043092134 @default.
- W4238774035 creator A5046329367 @default.
- W4238774035 creator A5050714925 @default.
- W4238774035 creator A5058427951 @default.
- W4238774035 creator A5060681737 @default.
- W4238774035 creator A5062493065 @default.
- W4238774035 creator A5068487815 @default.
- W4238774035 creator A5071541433 @default.
- W4238774035 creator A5089477356 @default.
- W4238774035 date "1998-12-01" @default.
- W4238774035 modified "2023-09-26" @default.
- W4238774035 title "Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist" @default.
- W4238774035 doi "https://doi.org/10.1002/1529-0131(199812)41:12<2196::aid-art15>3.3.co;2-u" @default.
- W4238774035 hasPublicationYear "1998" @default.
- W4238774035 type Work @default.
- W4238774035 citedByCount "16" @default.
- W4238774035 crossrefType "journal-article" @default.
- W4238774035 hasAuthorship W4238774035A5001588361 @default.
- W4238774035 hasAuthorship W4238774035A5004363203 @default.
- W4238774035 hasAuthorship W4238774035A5022630337 @default.
- W4238774035 hasAuthorship W4238774035A5026797171 @default.
- W4238774035 hasAuthorship W4238774035A5028429978 @default.
- W4238774035 hasAuthorship W4238774035A5037573724 @default.
- W4238774035 hasAuthorship W4238774035A5043092134 @default.
- W4238774035 hasAuthorship W4238774035A5046329367 @default.
- W4238774035 hasAuthorship W4238774035A5050714925 @default.
- W4238774035 hasAuthorship W4238774035A5058427951 @default.
- W4238774035 hasAuthorship W4238774035A5060681737 @default.
- W4238774035 hasAuthorship W4238774035A5062493065 @default.
- W4238774035 hasAuthorship W4238774035A5068487815 @default.
- W4238774035 hasAuthorship W4238774035A5071541433 @default.
- W4238774035 hasAuthorship W4238774035A5089477356 @default.
- W4238774035 hasConcept C126322002 @default.
- W4238774035 hasConcept C141071460 @default.
- W4238774035 hasConcept C14184104 @default.
- W4238774035 hasConcept C142724271 @default.
- W4238774035 hasConcept C168563851 @default.
- W4238774035 hasConcept C197934379 @default.
- W4238774035 hasConcept C198451711 @default.
- W4238774035 hasConcept C204787440 @default.
- W4238774035 hasConcept C27081682 @default.
- W4238774035 hasConcept C2776232647 @default.
- W4238774035 hasConcept C2776715498 @default.
- W4238774035 hasConcept C2777077863 @default.
- W4238774035 hasConcept C2777575956 @default.
- W4238774035 hasConcept C2778143017 @default.
- W4238774035 hasConcept C71924100 @default.
- W4238774035 hasConcept C90924648 @default.
- W4238774035 hasConceptScore W4238774035C126322002 @default.
- W4238774035 hasConceptScore W4238774035C141071460 @default.
- W4238774035 hasConceptScore W4238774035C14184104 @default.
- W4238774035 hasConceptScore W4238774035C142724271 @default.
- W4238774035 hasConceptScore W4238774035C168563851 @default.
- W4238774035 hasConceptScore W4238774035C197934379 @default.
- W4238774035 hasConceptScore W4238774035C198451711 @default.
- W4238774035 hasConceptScore W4238774035C204787440 @default.
- W4238774035 hasConceptScore W4238774035C27081682 @default.
- W4238774035 hasConceptScore W4238774035C2776232647 @default.
- W4238774035 hasConceptScore W4238774035C2776715498 @default.
- W4238774035 hasConceptScore W4238774035C2777077863 @default.
- W4238774035 hasConceptScore W4238774035C2777575956 @default.
- W4238774035 hasConceptScore W4238774035C2778143017 @default.
- W4238774035 hasConceptScore W4238774035C71924100 @default.
- W4238774035 hasConceptScore W4238774035C90924648 @default.
- W4238774035 hasIssue "12" @default.
- W4238774035 hasLocation W42387740351 @default.
- W4238774035 hasOpenAccess W4238774035 @default.
- W4238774035 hasPrimaryLocation W42387740351 @default.
- W4238774035 hasRelatedWork W2124094613 @default.
- W4238774035 hasRelatedWork W2139717997 @default.
- W4238774035 hasRelatedWork W2221029685 @default.
- W4238774035 hasRelatedWork W2581494937 @default.
- W4238774035 hasRelatedWork W2783466784 @default.
- W4238774035 hasRelatedWork W3007454014 @default.
- W4238774035 hasRelatedWork W4220849004 @default.
- W4238774035 hasRelatedWork W4287131916 @default.
- W4238774035 hasRelatedWork W4367294269 @default.
- W4238774035 hasRelatedWork W15427406 @default.
- W4238774035 hasVolume "41" @default.
- W4238774035 isParatext "false" @default.
- W4238774035 isRetracted "false" @default.
- W4238774035 workType "article" @default.